according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 5.0 2024/09/28 438898-00022 Date of first issue: 2016/01/06

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Ceftolozane / Tazobactam Injection Formulation

Manufacturer or supplier's details

Company : MSD

Address : 199 Wenhai North Road

HEDA, Hangzhou - Zhejiang Province - CHINA 310018

Telephone : 908-740-4000

Emergency telephone number : 86-571-87268110

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Emergency Overview

Appearance : powder

Colour : No data available
Odour : No data available
No data available

May cause allergy or asthma symptoms or breathing difficulties if inhaled. May cause damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects.

GHS Classification

Respiratory sensitisation : Category 1

Specific target organ toxicity - : Category 2

repeated exposure

Short-term (acute) aquatic :

hazard

Category 1

Long-term (chronic) aquatic

hazard

: Category 1

Hazaru

GHS label elements

according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 5.0 2024/09/28 438898-00022 Date of first issue: 2016/01/06

Hazard pictograms





Signal word : Danger

Hazard statements : H334 May cause allergy or asthma symptoms or breathing

difficulties if inhaled.

H373 May cause damage to organs through prolonged or re-

peated exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P260 Do not breathe dust.

P273 Avoid release to the environment. P284 Wear respiratory protection.

Response:

P304 + P340 IF INHALED: Remove person to fresh air and

keep comfortable for breathing.

P342 + P311 If experiencing respiratory symptoms: Call a

POISON CENTER/ doctor. P391 Collect spillage.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

Physical and chemical hazards

Not classified based on available information.

Health hazards

May cause allergy or asthma symptoms or breathing difficulties if inhaled. May cause damage to organs through prolonged or repeated exposure.

Environmental hazards

Very toxic to aquatic life. Very toxic to aquatic life with long lasting effects.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
---------------	---------	-----------------------

according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 5.0 2024/09/28 438898-00022 Date of first issue: 2016/01/06

Ceftolozane	689293-68-3	>= 30 -< 50
Tazobactam	89786-04-9	>= 10 -< 20
Sodium chloride	7647-14-5	>= 10 -< 20

4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

> If not breathing, give artificial respiration. If breathing is difficult, give oxygen.

Get medical attention.

In case of contact, immediately flush skin with soap and plenty In case of skin contact

of water.

Get medical attention if symptoms occur.

In case of eye contact If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and

delayed

May cause allergy or asthma symptoms or breathing difficul-

ties if inhaled.

May cause damage to organs through prolonged or repeated

exposure.

Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reac-

tive airways dysfunction syndrome).

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

First Aid responders should pay attention to self-protection, Protection of first-aiders

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formulation

Version 5.0

Revision Date: 2024/09/28

SDS Number: 438898-00022

Date of last issue: 2024/04/06 Date of first issue: 2016/01/06

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides Metal oxides

Chlorine compounds Nitrogen oxides (NOx)

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air. Add excess liquid to allow the material to enter into solution.

Soak up with inert absorbent material.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable absorband

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 5.0 2024/09/28 438898-00022 Date of first issue: 2016/01/06

7. HANDLING AND STORAGE

Handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Already sensitised individuals, and those susceptible

to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respira-

tory irritants or sensitisers.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Keep away from heat and sources of ignition. Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Avoidance of contact : Oxidizing agents

Storage

Conditions for safe storage : Keep in properly labelled containers.

Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Packaging material : Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis	
Ceftolozane	689293-68-3	TWA	1000 μg/m3 (OEB 1)	Internal	
	Further inform	Further information: DSEN, RSEN			
		Wipe limit	100 μg/100 cm ²	Internal	
Tazobactam	89786-04-9	TWA	250 µg/m3 (OEB	Internal	

according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 5.0 2024/09/28 438898-00022 Date of first issue: 2016/01/06

U			2)	
	Further information: RSEN			
		Wipe limit	100 μg/100 cm2	Internal

Engineering measures : Use feasible engineering controls to minimize exposure to

compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type : Particulates type

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection

Hand protection Material

d protection

Hygiene measures : If exposure to chemical is likely during typical use, provide

Chemical-resistant gloves

Work uniform or laboratory coat.

eye flushing systems and safety showers close to the work-

ing place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Colour : No data available

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formula- tion

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 5.0 2024/09/28 438898-00022 Date of first issue: 2016/01/06

Initial boiling point and boiling :

range

No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

10. STABILITY AND REACTIVITY

according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 5.0 2024/09/28 438898-00022 Date of first issue: 2016/01/06

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Oxidizing agents

Incompatible materials

Hazardous decomposition

products

No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation

Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

Components:

Ceftolozane:

Acute toxicity (other routes of :

administration)

LD50 (Rat): > 2,000 mg/kg Application Route: Intravenous

LD50 (Mouse): > 1,500 mg/kg Application Route: Intravenous

LD50 (Dog): > 2,000 mg/kg Application Route: Intravenous

Tazobactam:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

LD50 (Mouse): > 5,000 mg/kg

Acute toxicity (other routes of :

administration)

LD50 (Rat): > 5,000 mg/kg

Application Route: Intravenous

LD50 (Mouse): > 5,000 mg/kg Application Route: Intravenous

according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formula- tion

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 5.0 2024/09/28 438898-00022 Date of first issue: 2016/01/06

LD50 (Dog): > 5,000 mg/kg Application Route: Intravenous

Sodium chloride:

Acute oral toxicity : LD50 (Rat): 3,550 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 42 mg/l

Exposure time: 1 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Sodium chloride:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Sodium chloride:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Ceftolozane:

Test Type : Maximisation Test

Species : Guinea pig Result : Sensitiser

Tazobactam:

Result : Sensitiser

according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 5.0 2024/09/28 438898-00022 Date of first issue: 2016/01/06

Sodium chloride:

Test Type : Local lymph node assay (LLNA)

Exposure routes : Skin contact
Species : Mouse
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Ceftolozane:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: positive

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse Result: negative

Test Type: Unscheduled DNA synthesis (UDS) test with

mammalian liver cells in vivo

Species: Mouse Result: negative

Tazobactam:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: mouse lymphoma cells

Result: positive

Test Type: Chromosome aberration test in vitro

Test system: Chinese hamster fibroblasts

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formulation

Version Revision Date: 5.0 2024/09/28

SDS Number: 438898-00022

Date of last issue: 2024/04/06 Date of first issue: 2016/01/06

Application Route: Intraperitoneal injection

Result: negative

Test Type: Unscheduled DNA synthesis (UDS) test with

mammalian liver cells in vivo

Species: Mouse Result: negative

Sodium chloride:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: positive

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Saccharomyces cerevisiae, gene mutation assay

(in vitro) Result: positive

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)

Result: positive

Test Type: Chromosome aberration test in vitro

Result: positive

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Intraperitoneal injection

Result: positive

Germ cell mutagenicity -

Assessment

: Weight of evidence does not support classification as a germ

cell mutagen.

Carcinogenicity

Not classified based on available information.

according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 5.0 2024/09/28 438898-00022 Date of first issue: 2016/01/06

Components:

Sodium chloride:

Species: RatApplication Route: IngestionExposure time: 2 YearsResult: negative

Reproductive toxicity

Not classified based on available information.

Components:

Ceftolozane:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Intravenous injection Fertility: NOAEL: 1,000 mg/kg body weight

Result: No effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Intravenous injection

Developmental Toxicity: NOAEL: 2,000 mg/kg body weight Remarks: No significant adverse effects were reported

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intravenous injection

Developmental Toxicity: NOAEL: 1,000 mg/kg body weight Remarks: No significant adverse effects were reported

Tazobactam:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Intraperitoneal injection Fertility: NOAEL: 640 mg/kg body weight

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intraperitoneal injection

Developmental Toxicity: NOAEL: 40 mg/kg body weight

Result: Effects on early embryonic development

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intravenous injection

Developmental Toxicity: NOAEL: 3,000 mg/kg body weight

Result: No effects on foetal development

according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 5.0 2024/09/28 438898-00022 Date of first issue: 2016/01/06

П

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

Ceftolozane:

Target Organs : Kidney

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Tazobactam:

Target Organs : Liver

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Ceftolozane:

Species : Rat

NOAEL : 1,000 mg/kg
Application Route : Intravenous
Exposure time : 28 days
Target Organs : Kidney

Symptoms : No adverse effects

Species : Dog
LOAEL : 300 mg/kg
Exposure time : 28 days
Target Organs : Kidney

Tazobactam:

Species : Rat

NOAEL : 40 mg/kg

Application Route : Intraperitoneal

Exposure time : 6 Months

Target Organs : Liver

Species : Dog
NOAEL : 40 mg/kg
LOAEL : 80 mg/kg
Application Route : Intraperitoneal
Exposure time : 6 Months

according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 5.0 2024/09/28 438898-00022 Date of first issue: 2016/01/06

Target Organs : Liver

Sodium chloride:

Species : Rat

LOAEL : 2,533 mg/kg
Application Route : Ingestion
Exposure time : 2 yr

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Ceftolozane:

Ingestion : Symptoms: Diarrhoea, Fever, Headache, Nausea, Skin irrita-

tion, Gastrointestinal discomfort

Tazobactam:

Inhalation : Remarks: May cause allergy or asthma symptoms or breath-

ing difficulties if inhaled.

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Ceftolozane:

Toxicity to algae/aquatic : EC50 (Anabaena flos-aquae): 0.0401 mg/l

plants Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae): 0.0018 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox- : 10

city

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 10 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 9.6 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

M-Factor (Chronic aquatic : 10

according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 5.0 2024/09/28 438898-00022 Date of first issue: 2016/01/06

toxicity)

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 560 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Tazobactam:

Toxicity to algae/aquatic : EC50 (Anabaena flos-aquae): 0.96 mg/l

1

plants Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae): 0.44 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox- :

icity,

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 10.6 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 9.6 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Sodium chloride:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): 5,840 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 4,136 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic : EC50: > 2,000 mg/l

according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 Date of first issue: 2016/01/06 2024/09/28 438898-00022 5.0

plants Exposure time: 96 h

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 252 mg/l

NOEC (Daphnia pulex (Water flea)): 314 mg/l

Exposure time: 33 d

Toxicity to daphnia and other: aguatic invertebrates (Chron-

Exposure time: 21 d

ic toxicity)

Toxicity to microorganisms : EC10: > 1,000 mg/l

Persistence and degradability

Components:

Ceftolozane:

Biodegradability Result: Not readily biodegradable.

Method: OECD Test Guideline 301D

Tazobactam:

Biodegradability Result: Not readily biodegradable.

Method: OECD Test Guideline 301D

Bioaccumulative potential

Components:

Ceftolozane:

Partition coefficient: n-

: log Pow: -0.21

octanol/water

Tazobactam:

Partition coefficient: n-

log Pow: -0.63

octanol/water

Mobility in soil

Components:

Ceftolozane:

Distribution among environ- : log Koc: 3.3 mental compartments

Method: OECD Test Guideline 106

Tazobactam:

Distribution among environmental compartments

: log Koc: 0.87

Other adverse effects

No data available

according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 5.0 2024/09/28 438898-00022 Date of first issue: 2016/01/06

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Ceftolozane, Tazobactam)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.

(Ceftolozane, Tazobactam)

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo : 956

aircraft)

Packing instruction (passen-

: 956

ger aircraft)

Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Ceftolozane, Tazobactam)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formula- tion

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 5.0 2024/09/28 438898-00022 Date of first issue: 2016/01/06

National Regulations

GB 6944/12268

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Ceftolozane, Tazobactam)

Class : 9
Packing group : III
Labels : 9
Marine pollutant : no

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

National regulatory information

Law on the Prevention and Control of Occupational Diseases

Regulations on Safety Management of Hazardous Chemicals

Catalogue of Hazardous Chemicals : This product is not listed in the cata-

logue of hazardous chemicals, but it meets the definition of hazardous chemicals and its principles of de-

termination.

Identification of Major Hazard Installations for Hazardous Chemicals (GB : Not listed

18218)

Hazardous Chemicals for Priority Management under : Not listed

SAWS

Regulations on Labour Protection in Workplaces where Toxic Substances are Used

Catalogue of Highly Toxic Chemicals : Not listed

Regulation of Environmental Management on the First Import of Chemicals and the Import and Export of Toxic Chemicals

China Severely Restricted Toxic Chemicals for Import : Not listed

and Export

Regulation on the Administration of Precursor Chemicals

Catalogue and Classification of Precursor Chemicals : Not listed

according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 5.0 2024/09/28 438898-00022 Date of first issue: 2016/01/06

Yangtze River Protection Law

This product does not contain any dangerous chemicals prohibited for inland river transport.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 2024/09/28

Further information

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation: DSL - Domestic Substances List (Canada): ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substanc-

according to GB/T 16483 and GB/T 17519



Ceftolozane / Tazobactam Injection Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 5.0 2024/09/28 438898-00022 Date of first issue: 2016/01/06

es; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN